Best of ASCO - 2014 Annual Meeting

 

Welcome

Cervical Cancer

Gynecologic Cancer

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A phase 1/2A trial of synthetic DNA vaccine immunotherapy targeting HPV-16 and -18 after chemoradiation for cervical cancer.

Yasmin Hasan

5525

A phase 2, multicenter study to evaluate the efficacy and safety using autologous tumor infiltrating lymphocytes (LN-145) in patients with recurrent, metastatic, or persistent cervical carcinoma.

Amir A. Jazaeri

TPS5604

A phase II evaluation of nivolumab, a fully human antibody against PD-1, in the treatment of persistent or recurrent cervical cancer.

Alessandro Santin

5536

A randomized phase II/III trial of conventional paclitaxel and carboplatin (cTC) versus dose-dense paclitaxel and carboplatin (ddTC), with or without bevacizumab (Bmab), for stage IVb, recurrent, or persistent cervical cancer (CC): Japan Clinical Oncology Group study (JCOG1311).

Ryo Kitagawa

TPS5603

A single arm, phase 2, multicenter, international trial of tisotumab vedotin (HuMax-TF-ADC) in previously treated, recurrent or metastatic cervical cancer.

Robert L. Coleman

TPS5601

AMPATH Oncology: Baseline HPV detection in Kenyan women enrolled in a longitudinal study of modifiable factors predicting cervical dysplasia.

Darron R. Brown

5533

Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: Interim results from the phase 2 KEYNOTE-100 study.

Ursula A. Matulonis

5511

Association between pap abnormalities and HPV infection in participants in HPV vaccine clinical trials.

Evan Meyers

5530

Association of age, race, and public health insurance with stage of cervical cancer at diagnosis in Brazil: Results of the EVITA cohort study (LACOG0215).

Angelica Nogueira Rodrigues

e17509

Clinical relevance of PD-L1 expression and its relation to tumor-infiltrating lymphocytes in cervical cancer.

Rafael Grochot

e17511

Comparison of different adjuvant therapy after radical surgery in early stage cervical carcinoma: A 3-arm randomized control study.

He Huang

5529

Dose dense neoadjuvant chemotherapy (NACT) with carboplatin-paclitaxel in locally advanced cervical cancer.

Domenica Lorusso

5534

Evaluation of capecitabine in patients with platinum-pretreated advanced or recurrent cervical carcinoma: A retrospective study of the IRCCS National Cancer Institute of Milan.

Domenica Lorusso

5535

Factors predicting learning curve, morbidity, mortality, and outcomes: A prospective phase III study of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal surface malignancy—First Indian study.

S.P. Somashekhar

e17512

GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase 3 trial of cemiplimab, an anti-PD-1, versus investigator's choice (IC) chemotherapy in ≥2 line recurrent or metastatic cervical cancer.

Krishnansu Sujata Tewari

TPS5600

Lost annual productivity costs due to cervical cancer deaths in the United States in 2014.

Shelby Corman

e17513

MicroRNA (miR) 203a as a biomarker of response to immunotherapy of HPV related cervical cancer.

Linda Li

e17508

Neoadjuvant chemotherapy with cisplatin and gemcitabine followed by chemoradiation with cisplatin in locally advanced cervical cancer: A phase II, prospective, randomized, trial.

Samantha Silva

5523

Neoadjuvant chemotherapy with gemcitabine and cisplatin followed by chemoradiation in locally aadvanced cervical cancer.

Abdul Mateen

e17501

Neuroendocrine carcinoma of the uterine cervix: A retrospective monocentric study.

Morgane Creoff

e17502

Outcomes and costs of open, robotic, and laparoscopic radical hysterectomy for stage IB1 cervical cancer.

Daniel Jacob Margul

5502

Ovarian preservation among women with early stage cervical cancer. A retrospective evaluation of the incidence of ovarian metastasis.

Jimmy A Billod

e17504

Pembrolizumab treatment of advanced cervical cancer: Updated results from the phase 2 KEYNOTE-158 study.

Hyun Cheol Chung

5522

Phase II clinical trial of eribulin (E) in advanced/recurrent cervical cancer.

Jocelyn Garcia

5526

Predictive factors of surgical morbidity for early-stage cervical cancer management: A prospective multicentric cohort of 228 patients.

Vincent Balaya

e17506

Preliminary results from CECILIA, an open-label global safety study of bevacizumab (BEV), carboplatin (C) and paclitaxel (P) therapy for metastatic, recurrent or persistent cervical cancer (CC).

Andres Redondo

5528

Prognostic significance of VEGF-A expression in patients with cervical cancer.

Oleg Ivanovich Kit

e17505

Propensity score-matched analysis of systemic chemotherapy versus hysterectomy for patients with residual cervical disease after definitive radiotherapy/concurrent chemoradiotherapy.

Munetaka Takekuma

5527

Reduction in time between cervical cancer diagnosis and treatment.

Carla Rameri Alexandre Silva De Azevedo

e17514

Safety and effectiveness of bevacizumab plus chemotherapy in patients with advanced cervical cancer in real world practice in Argentina.

Juan Jose Zarba

e17500

SENTICOL III: International validation study of sentinel node biopsy in early cervical cancer: A GINECO, ENGOT and GCIG study.

Fabrice Lecuru

TPS5602

Social disparities and patients’ attitudes are associated with lower rates of cervical cancer screening in Brazil: Results of EVITA study (LACOG 0215).

Angelica Nogueira Rodrigues

e17510

The clinical utility of prospective molecular characterization in advanced cervical and vulvovaginal cancer.

Claire Frances Friedman

5531

Unexpected lymphatic drainage pathways of cervical cancer: Insights of the sentinel lymph node biopsy.

Vincent Balaya

5532